FMT

MiDOG Animal Diagnostics Revolutionizes Veterinary Care with Expanded Diagnostic Solutions for All Animal Species

Retrieved on: 
Monday, February 19, 2024
DNA sequencing, Therapy, Infection, Bird, Amphibian, Reptile, DVM, Veterinary medicine, Ageing, Culture, Animal, Dog, NGS, Veterinarian, University, Health, Oral hygiene, Cat, Mammal, Patient, Diagnosis, FMT, Research, AMR, Vaccine

TUSTIN, Calif., Feb. 19, 2024 /PRNewswire/ -- MiDOG Animal Diagnostics LLC, a prominent leader in microbiome-based veterinary diagnostic solutions employing Next Generation DNA Sequencing analysis, has unveiled a revamped branding strategy in 2024.

Key Points: 
  • TUSTIN, Calif., Feb. 19, 2024 /PRNewswire/ -- MiDOG Animal Diagnostics LLC, a prominent leader in microbiome-based veterinary diagnostic solutions employing Next Generation DNA Sequencing analysis, has unveiled a revamped branding strategy in 2024.
  • The updated branding emphasizes the adaptability of MiDOG's technology across all animal species, departing from its previous emphasis on canine diagnostics.
  • By extending its diagnostic capabilities to encompass a diverse range of animal species, MiDOG aims to equip veterinarians with the tools needed to address acute, chronic, and non-responsive infections effectively.
  • The innovation at MiDOG Animal Diagnostics LLC is its microbiome-based comprehensive test, covering bacterial, fungal, and antimicrobial resistance (AMR) analysis.

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Retrieved on: 
Tuesday, October 31, 2023
NGB, Drug discovery, Doctor of Philosophy, Death, HBI, CDC, ARB, Microbiota, Biobank, Public, FMT, Cancer, Patient, Platform, Antibiotics

WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.

Key Points: 
  • WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.
  • Antibiotic resistance is a growing threat to public health, and new treatments are urgently needed.
  • The New-Generation Biotherapeutic (NGB) drug candidate has the potential to provide a new paradigm in preventing antibiotic-resistant bacteria (ARB) infections.
  • Now, we have predicted fully synthetic microbiome drug composition and our AI-based analysis confirms its efficacy – commented CEO and R&D Director of Human Biome Jaroslaw Bilinski MD, PhD.

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Retrieved on: 
Tuesday, October 31, 2023
NGB, Drug discovery, Doctor of Philosophy, Death, HBI, CDC, ARB, Microbiota, Biobank, Public, FMT, Cancer, Patient, Platform, Antibiotics

WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.

Key Points: 
  • WARSAW, Poland, Oct. 31, 2023 /PRNewswire/ -- This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology.
  • Antibiotic resistance is a growing threat to public health, and new treatments are urgently needed.
  • The New-Generation Biotherapeutic (NGB) drug candidate has the potential to provide a new paradigm in preventing antibiotic-resistant bacteria (ARB) infections.
  • Now, we have predicted fully synthetic microbiome drug composition and our AI-based analysis confirms its efficacy – commented CEO and R&D Director of Human Biome Jaroslaw Bilinski MD, PhD.

Kanvas Biosciences Acquires Federation Bio Assets to Scale the Discovery, Development and Manufacturing of Microbiome-Based Therapeutics

Retrieved on: 
Wednesday, October 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Health Technology, Partnership, DSM-IV codes, Lung cancer, FMT, Acquisition, LBP, Genetic distance, Google Maps, Dysbiosis, Biology, Piper LBP, Translational research, Intellectual property, Therapy, Surgical oncology, Recurrence, Cancer, MD Anderson Cancer Center, Federation, Melanoma, University, Immunotherapy, Inflammatory bowel disease, Monroe Dunaway Anderson, Lion Capital LLP, Patient, Pharmaceutical industry, Medical imaging, Nature

The deal also expands the company’s leadership and West Coast presence with the addition of Lee Swem , formerly Federation Bio’s Chief Science Officer, who joined Kanvas Biosciences as Chief Development Officer.

Key Points: 
  • The deal also expands the company’s leadership and West Coast presence with the addition of Lee Swem , formerly Federation Bio’s Chief Science Officer, who joined Kanvas Biosciences as Chief Development Officer.
  • “Kanvas Biosciences is leading the way in understanding exactly how the microbiome benefits human health.
  • With novel spatial biology and manufacturing platforms, Kanvas Biosciences is creating a first-in-category company capable of leveraging complex microbial therapies with hundreds of members simultaneously.
  • With early pre-clinical data showing promising results, Kanvas Biosciences and MD Anderson will soon begin drug manufacturing.

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Retrieved on: 
Thursday, September 28, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Thyroid nodule, Database, American Thyroid Association, ATA, Classification, Cancer, BRAF, RNA, Washington University in St. Louis, FMT, Thyroid cancer, FNA, Aggression, Patient, ERK, GRID, Endocrinology, Immunohistochemistry, Diagnosis, NIS, UCLA, GSC, Malignancy, Thyroid, VI, Prostate cancer, Johns Hopkins School of Medicine, Medical imaging, Pharmaceutical industry, Medicine

(Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type of novel molecular insights for thyroid nodules and cancer that are enabled by analysis with the Afirma Genomic Sequencing Classifier (GSC).

Key Points: 
  • (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type of novel molecular insights for thyroid nodules and cancer that are enabled by analysis with the Afirma Genomic Sequencing Classifier (GSC).
  • Presented by clinical researchers in three posters, the findings are based on Afirma whole-transcriptome RNA sequencing data and reveal novel molecular profiles to advance research of thyroid nodules and cancer.
  • Their study was based on a retrospective analysis of nearly 48,000 thyroid nodules analyzed with the Afirma GSC, confirming that the classifier identified the expected immunophenotype for a specific type of thyroid cancer molecular alteration.
  • “We are excited to soon make this new tool available to the thyroid cancer research community,” said Dr. Klopper.

Riding the Early Adoption Wave Created by Ferring's Rebyota, Aimmune's Vowst, is Set to Provide a New Fecal Microbiota Transplant (FMT) Option for Patients Struggling with Recurrent Clostridioides Difficile, According to Spherix Global Insights

Retrieved on: 
Tuesday, May 23, 2023
Ferring Pharmaceuticals, Headwinds, Infection, Gastroenterology, FMT, Microbiota, CDC, Patient, Physician, Clostridioides difficile, Transplant, FDA, Recurrence, Pharmaceutical industry, Clostridioides difficile infection, Fecal microbiota

EXTON, Pa., May 23, 2023 /PRNewswire/ -- Prior to Ferring Pharmaceuticals' Rebyota, physicians interested in using fecal microbiota transplants (FMT) to treat patients with recurrent clostridioides difficile (C.Diff) had to turn to specialized centers using off-label processes to synthesize an FMT formulation. The FDA approval of Rebyota provided a welcomed level of clinical and public assurance that the manufacturing process used to create microbiota treatments from human fecal material is well regulated and safe.  

Key Points: 
  • Gastroenterologist staff must perform additional work to coordinate patient schedules with procurement, storage, and preparation of the therapy for delivery.
  • Vowst, the first approved orally delivered FMT avoids these burdens, allowing patients to treat themselves at home, with no extraordinary storage concerns.
  • FMT therapy promises to help reduce the burden of recurrent disease when used earlier in the recurrence cycle.
  • Spherix will begin tracking Vowst alongside Rebyota once the new oral therapy becomes available for doctors to prescribe in June or July.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

AMEND PET AND ASSOCIATION OF SHELTER VETERINARIANS PARTNER TO EXPAND ACCESS TO FECAL MICROBIOTA TRANSPLANT FOR TREATING DIARRHEA IN SHELTER PETS

Retrieved on: 
Wednesday, May 10, 2023
Enema, Partnership, Dysbiosis, Diarrhea, Veterinarian, FMT, Trust, Animal, Patient, ASV, Dog, Pet, Colonoscopy, Health, Veterinary medicine, Management

SEATTLE, May 10, 2023 /PRNewswire/ -- Amend Pet ("the company"), a microbiome solutions company, today announced the launch of its partnership with the Association of Shelter Veterinarians (ASV) to provide ASV members affordable, easy-to-administer Fecal Microbiota Transplant Therapy (FMT) and microbiome testing to assess dogs for dysbiosis. FMT is a proven treatment for recurrent diarrhea in pets, but until now has been too labor intensive and costly for veterinarians to widely utilize.

Key Points: 
  • FMT is a proven treatment for recurrent diarrhea in pets, but until now has been too labor intensive and costly for veterinarians to widely utilize.
  • Amend Pet's FMT capsule device and testing solution allows veterinarians to prepare multiple transplant regimens in 5-10 minutes in their own facility from pet donors they know and trust.
  • "We are excited to support ASV Veterinarians who maximize limited resources to provide a vital service for countless animals", said Mike Goonewardene, CEO of Amend Pet.
  • "Our partnership with Amend Pet opens the door to innovative products and services in a vital area of care, digestive health, for animals residing in shelters across the country".

Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights

Retrieved on: 
Friday, March 17, 2023
Enema, Ferring Pharmaceuticals, Macrogol, Clostridioides, Physician, Infection, Gastroenterology, Research, Temperature, Launch, FMT, Patient, Fecal microbiota transplant, Clostridioides difficile, FDA, Recurrence, Disease, Pharmaceutical industry

EXTON, Pa., March 17, 2023 /PRNewswire/ -- When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant breakthrough doctors treating the disease have seen in years. Rebyota falls in the class of therapy known as Fecal Microbiota Transplant, or FMT, a therapy over 60% of treating gastroenterologists believe will dramatically change the paradigm of C.diff treatment in the next five years, according to research from Spherix Global Insights Market Dynamix™ Clostridioides Difficile (US) service.

Key Points: 
  • At least two additional FMT treatments are in development for C.diff, including Aimmune/Seres' SER-109 and Vedanta Biosciences' VE303.
  • With a first to market advantage, Ferring's Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch.
  • As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
  • A few headwinds Ferring may be facing with Rebyota include its mode of administration, and storage and handling requirements.